Impact on PMNSo we have two companies that have publically shown that their treatment for AD is working.to some extent. Yes the data is not overwhelming , the drugs are not perfect, but so far this has been the most positive news in at least 10 years . Here is a link to a reputable grooup and in this article a very important point is made ... this is what impacts PMN's future .... pretty clear. about what other companies need to hear inorder to push them to proceed in the same direction..
https://www.alzforum.org/news/research-news/phase-2-donanemab-curbs-cognitive-decline-early-alzheimers
It’s a good day for the field,” said Eric Siemers of Siemers Integration, LLC, who worked at Lilly when the trial began but has since retired. “We now have one more monoclonal antibody signaling in the right direction.”
Cynthia Lemere of Brigham and Women’s Hospital in Boston welcomed the news. “Lilly’s Phase 2 positive findings lend further support to the amyloid hypothesis and validate Aβ as a therapeutic target for early-stage AD,” she wrote (full comment below).